Logo image of GMAB

GENMAB A/S -SP ADR (GMAB) Stock Overview

NASDAQ:GMAB - US3723032062 - ADR

24.65 USD
+0.23 (+0.94%)
Last: 8/22/2025, 8:12:21 PM
24.58 USD
-0.07 (-0.28%)
Pre-Market: 8/25/2025, 5:14:17 AM

GMAB Key Statistics, Chart & Performance

Key Statistics
52 Week High27.94
52 Week Low17.24
Market Cap15.16B
Shares615.07M
Float589.67M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0.59
PE41.78
Fwd PE80.73
Earnings (Next)11-06 2025-11-06/bmo
IPO10-01 2000-10-01
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


GMAB short term performance overview.The bars show the price performance of GMAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

GMAB long term performance overview.The bars show the price performance of GMAB in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of GMAB is 24.65 USD. In the past month the price increased by 5.34%. In the past year, price decreased by -9.84%.

GENMAB A/S -SP ADR / GMAB Daily stock chart

GMAB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.89 372.04B
AMGN AMGEN INC 13.47 158.13B
GILD GILEAD SCIENCES INC 14.83 142.41B
VRTX VERTEX PHARMACEUTICALS INC 23.32 101.30B
REGN REGENERON PHARMACEUTICALS 12.92 62.48B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.56B
ARGX ARGENX SE - ADR 71.2 40.39B
ONC BEONE MEDICINES LTD-ADR 6.35 37.29B
INSM INSMED INC N/A 27.88B
BNTX BIONTECH SE-ADR N/A 26.66B
NTRA NATERA INC N/A 22.73B
BIIB BIOGEN INC 8.7 20.42B

About GMAB

Company Profile

GMAB logo image Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Company Info

GENMAB A/S -SP ADR

Carl Jacobsens Vej 30

Valby 1560 DK

CEO: Jan G. J. van de Winkel

Employees: 2682

GMAB Company Website

GMAB Investor Relations

Phone: 4570202728

GENMAB A/S -SP ADR / GMAB FAQ

What is the stock price of GENMAB A/S -SP ADR today?

The current stock price of GMAB is 24.65 USD. The price increased by 0.94% in the last trading session.


What is the ticker symbol for GENMAB A/S -SP ADR stock?

The exchange symbol of GENMAB A/S -SP ADR is GMAB and it is listed on the Nasdaq exchange.


On which exchange is GMAB stock listed?

GMAB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GENMAB A/S -SP ADR stock?

29 analysts have analysed GMAB and the average price target is 99.61 USD. This implies a price increase of 304.12% is expected in the next year compared to the current price of 24.65. Check the GENMAB A/S -SP ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENMAB A/S -SP ADR worth?

GENMAB A/S -SP ADR (GMAB) has a market capitalization of 15.16B USD. This makes GMAB a Large Cap stock.


How many employees does GENMAB A/S -SP ADR have?

GENMAB A/S -SP ADR (GMAB) currently has 2682 employees.


What are the support and resistance levels for GENMAB A/S -SP ADR (GMAB) stock?

GENMAB A/S -SP ADR (GMAB) has a support level at 21.43 and a resistance level at 24.66. Check the full technical report for a detailed analysis of GMAB support and resistance levels.


Is GENMAB A/S -SP ADR (GMAB) expected to grow?

The Revenue of GENMAB A/S -SP ADR (GMAB) is expected to grow by 20.63% in the next year. Check the estimates tab for more information on the GMAB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENMAB A/S -SP ADR (GMAB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENMAB A/S -SP ADR (GMAB) stock pay dividends?

GMAB does not pay a dividend.


When does GENMAB A/S -SP ADR (GMAB) report earnings?

GENMAB A/S -SP ADR (GMAB) will report earnings on 2025-11-06, before the market open.


What is the Price/Earnings (PE) ratio of GENMAB A/S -SP ADR (GMAB)?

The PE ratio for GENMAB A/S -SP ADR (GMAB) is 41.78. This is based on the reported non-GAAP earnings per share of 0.59 and the current share price of 24.65 USD. Check the full fundamental report for a full analysis of the valuation metrics for GMAB.


What is the Short Interest ratio of GENMAB A/S -SP ADR (GMAB) stock?

The outstanding short interest for GENMAB A/S -SP ADR (GMAB) is 0.61% of its float. Check the ownership tab for more information on the GMAB short interest.


GMAB Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to GMAB. When comparing the yearly performance of all stocks, GMAB turns out to be only a medium performer in the overall market: it outperformed 47.22% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

GMAB Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to GMAB. Both the health and profitability get an excellent rating, making GMAB a very profitable company, without any liquidiy or solvency issues.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GMAB Financial Highlights

Over the last trailing twelve months GMAB reported a non-GAAP Earnings per Share(EPS) of 0.59. The EPS decreased by -56.11% compared to the year before.


Industry RankSector Rank
PM (TTM) 35.1%
ROA 17.22%
ROE 21.42%
Debt/Equity 0.02
Chartmill High Growth Momentum
EPS Q2Q%-75.02%
Sales Q2Q%-82.88%
EPS 1Y (TTM)-56.11%
Revenue 1Y (TTM)30.57%

GMAB Forecast & Estimates

29 analysts have analysed GMAB and the average price target is 99.61 USD. This implies a price increase of 304.12% is expected in the next year compared to the current price of 24.65.

For the next year, analysts expect an EPS growth of -77.29% and a revenue growth 20.63% for GMAB


Analysts
Analysts77.24
Price Target99.61 (304.1%)
EPS Next Y-77.29%
Revenue Next Year20.63%

GMAB Ownership

Ownership
Inst Owners35.41%
Ins OwnersN/A
Short Float %0.61%
Short Ratio2.75